Table 2.
Immunophenotypic markers in the blastic population in BPDCN cases
| Immunophenotype | Positive result/tested (%) |
|---|---|
| BPDC markers | |
| CD4+ CD56+ CD123+ | 391/398 (96) |
| CD4− and/or CD56− CD123+ TCL1+ BDCA2+ | 13 (3) |
| CD4+ CD56+ CD123− TCL1+ and/or BDCA2+ | 3 (1) |
| CD4+ CD56+ CD123+ TCL1+ and/or BDCA2+ | 192/227 (85) |
| CD4+ CD56+ CD123+ TCL1+ BDCA2+ | 35/98 (36) |
| BDCA4 | 13/17 (76) |
| T-lymphoid and natural killer cell markers | |
| CD3 | 0/398 (0) |
| cCD3 | 0/398 (0) |
| CD8 | 0/130 (0) |
| CD16 | 0/82 (0) |
| TIA | 0/60 (0) |
| CD1 | 1/46 (2) |
| CD57 | 1/42 (2) |
| Granzyme | 1/56 (2) |
| CD5 | 4/116 (3) |
| CD2 | 47/146 (32) |
| CD7 | 75/ 191 (39) |
| B-lymphoid markers | |
| CD19 | 0/142 (0) |
| CD20 | 0/348 (0) |
| cCD22 | 0/65 (0) |
| PAX5 | 0/15 (0) |
| CD138 | 1/41 (2) |
| cCD79a | 6/201 (3) |
| Myeloid and monocyte markers | |
| Myeloperoxidase | 0/398 (0) |
| CD11c | 0/169 (0) |
| Lysozyme | 0/77 (0) |
| CD14 | 0/72 (0) |
| CD15 | 0/64 (0) |
| CD64 | 1/40 (2) |
| CD13 | 2/98 (2) |
| CD117 | 16/107 (15) |
| CD33 | 51/152 (34) |
| CD68 | 93/167 (56) |
| CD36 | 31/36 (86) |
| Immature and other markers | |
| CD34 | 5/205 (2) |
| CD30 | 1/65 (1.5) |
| CD45Ro | 1/43 (2) |
| CD10 | 4/92 (4) |
| S100 | 13/63 (20) |
| CD38 | 14/56 (25) |
| TdT | 82/230 (36) |
| MX1 | 27/47 (57) |
| BCL2 | 16/22 (73) |
| CD2AP | 8/10 (80) |
| CD43 | 99/103 (96) |
| CD45RA | 124/128 (97) |
| HLA-DR | 119/121 (98) |
BPDC, blastic plasmacytoid dendritic cell; cCD22, cytoplasmic CD22; cCD3, cytoplasmic CD3; cCD79a, cytoplasmic CD79a; CD2AP, CD2-associated protein.